194 related articles for article (PubMed ID: 23172636)
1. Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis.
Tawbi HA; Beumer JH; Tarhini AA; Moschos S; Buch SC; Egorin MJ; Lin Y; Christner S; Kirkwood JM
Ann Oncol; 2013 Apr; 24(4):1112-9. PubMed ID: 23172636
[TBL] [Abstract][Full Text] [Related]
2. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
Agarwala SS; Kirkwood JM
Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
[TBL] [Abstract][Full Text] [Related]
4. A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
Tarhini AA; Kirkwood JM; Gooding WE; Moschos S; Agarwala SS
Cancer; 2008 Oct; 113(7):1632-40. PubMed ID: 18720480
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Spieth K; Kaufmann R; Dummer R; Garbe C; Becker JC; Hauschild A; Tilgen W; Ugurel S; Beyeler M; Bröcker EB; Kaehler KC; Pföhler C; Gille J; Leiter U; Schadendorf D
Ann Oncol; 2008 Apr; 19(4):801-6. PubMed ID: 18178958
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide and cisplatin in avdanced malignant melanoma.
Daponte A; Ascierto PA; Gravina A; Melucci M; Scala S; Ottaiano A; Simeone E; Palmieris G; Comella G
Anticancer Res; 2005; 25(2B):1441-7. PubMed ID: 15865103
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Gogas H; Polyzos A; Stavrinidis I; Frangia K; Tsoutsos D; Panagiotou P; Markopoulos C; Papadopoulos O; Pectasides D; Mantzourani M; Middleton M; Vaiopoulos G; Fountzilas G
Ann Oncol; 2006 Dec; 17(12):1835-41. PubMed ID: 16980601
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
Bafaloukos D; Gogas H; Georgoulias V; Briassoulis E; Fountzilas G; Samantas E; Kalofonos Ch; Skarlos D; Karabelis A; Kosmidis P
J Clin Oncol; 2002 Jan; 20(2):420-5. PubMed ID: 11786569
[TBL] [Abstract][Full Text] [Related]
9. First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).
von Moos R; Seifert B; Simcock M; Goldinger SM; Gillessen S; Ochsenbein A; Michielin O; Cathomas R; Schläppi M; Moch H; Schraml PH; Mjhic-Probst D; Mamot C; Schönewolf N; Dummer R;
Ann Oncol; 2012 Feb; 23(2):531-6. PubMed ID: 21527587
[TBL] [Abstract][Full Text] [Related]
10. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Schadendorf D; Hauschild A; Ugurel S; Thoelke A; Egberts F; Kreissig M; Linse R; Trefzer U; Vogt T; Tilgen W; Mohr P; Garbe C
Ann Oncol; 2006 Oct; 17(10):1592-7. PubMed ID: 17005632
[TBL] [Abstract][Full Text] [Related]
11. Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
Fateh S; Schell TD; Gingrich R; Neves RI; Drabick JJ
Cancer Biol Ther; 2010 Dec; 10(11):1091-7. PubMed ID: 20930514
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
Clark JI; Moon J; Hutchins LF; Sosman JA; Kast WM; Da Silva DM; Liu PY; Thompson JA; Flaherty LE; Sondak VK
Cancer; 2010 Jan; 116(2):424-31. PubMed ID: 19918923
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.
Laber DA; Okeke RI; Arce-Lara C; Taft BS; Schonard CL; McMasters KM; Kloecker GH; Miller DM
J Cancer Res Clin Oncol; 2006 Sep; 132(9):611-6. PubMed ID: 16741726
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
Ranson M; Hersey P; Thompson D; Beith J; McArthur GA; Haydon A; Davis ID; Kefford RF; Mortimer P; Harris PA; Baka S; Seebaran A; Sabharwal A; Watson AJ; Margison GP; Middleton MR
J Clin Oncol; 2007 Jun; 25(18):2540-5. PubMed ID: 17577032
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR
J Clin Oncol; 2003 Jul; 21(13):2551-7. PubMed ID: 12829675
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
Bael TE; Peterson BL; Gollob JA
Melanoma Res; 2008 Apr; 18(2):147-51. PubMed ID: 18337652
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.
Dronca RS; Allred JB; Perez DG; Nevala WK; Lieser EA; Thompson M; Maples WJ; Creagan ET; Pockaj BA; Kaur JS; Moore TD; Marchello BT; Markovic SN
Am J Clin Oncol; 2014 Aug; 37(4):369-76. PubMed ID: 23357973
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
Hwu WJ; Lis E; Menell JH; Panageas KS; Lamb LA; Merrell J; Williams LJ; Krown SE; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
Cancer; 2005 Jun; 103(12):2590-7. PubMed ID: 15861414
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Middleton MR; Friedlander P; Hamid O; Daud A; Plummer R; Falotico N; Chyla B; Jiang F; McKeegan E; Mostafa NM; Zhu M; Qian J; McKee M; Luo Y; Giranda VL; McArthur GA
Ann Oncol; 2015 Oct; 26(10):2173-9. PubMed ID: 26202595
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.
Bafaloukos D; Tsoutsos D; Kalofonos H; Chalkidou S; Panagiotou P; Linardou E; Briassoulis E; Efstathiou E; Polyzos A; Fountzilas G; Christodoulou C; Kouroussis C; Iconomou T; Gogas H
Ann Oncol; 2005 Jun; 16(6):950-7. PubMed ID: 15829494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]